000170192 001__ 170192
000170192 005__ 20240229133707.0
000170192 0247_ $$2doi$$a10.2147/CLEP.S318737
000170192 0247_ $$2pmid$$apmid:34377034
000170192 0247_ $$2pmc$$apmc:PMC8349530
000170192 0247_ $$2altmetric$$aaltmetric:111116038
000170192 037__ $$aDKFZ-2021-01815
000170192 041__ $$aEnglish
000170192 082__ $$a610
000170192 1001_ $$0P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aZheng, Guoqiao$$b0$$eFirst author$$udkfz
000170192 245__ $$aSecond Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers.
000170192 260__ $$aAlbany, Auckland$$bDove Medical Press$$c2021
000170192 3367_ $$2DRIVER$$aarticle
000170192 3367_ $$2DataCite$$aOutput Types/Journal article
000170192 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1629110980_30630
000170192 3367_ $$2BibTeX$$aARTICLE
000170192 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000170192 3367_ $$00$$2EndNote$$aJournal Article
000170192 500__ $$a#EA:C020#
000170192 520__ $$aSecond primary cancers (SPCs) are important clinically as they may negatively influence patient survival and they may tell about therapeutic side effects and general causes of cancer. Population-based literature concerning SPCs after hepatobiliary cancers is limited and here we assess risks of SPCs after hepatocellular cancer (HCC), and cancers of the gallbladder, bile ducts and ampulla of Vater. In reverse order, we consider the risk of hepatobiliary cancers as SPCs after any cancer.We used standardized incidence ratios (SIRs) to estimate bidirectional relative risks of subsequent cancers associated with hepatobiliary cancers. Cancer diagnoses were obtained from the Swedish Cancer Registry from years 1990 through 2015.We identified 9997 primary HCCs, 1365 gallbladder cancers and 4721 bile duct cancers. After HCC, risks of four SPCs were increased: gallbladder (SIR = 4.38; 95% confidence interval 1.87-8.67), thyroid (4.13; 1.30-9.70), kidney (2.92; 1.66-4.47) and squamous cell skin (1.55; 1.02-2.26) cancers. In reverse order, HCC as SPC, in addition to the above cancers, associations included upper aerodigestive tract, esophageal, small intestinal and bladder cancers and non-Hodgkin lymphoma. For gallbladder and bile duct cancers, associations were found with small intestinal and pancreatic cancers.The results suggested that HCC is associated with two types of SPC, one related to shared environmental risk factors, such as alcohol, exemplified by upper aerodigestive tract and esophageal cancer, and the other related to immune dysfunction, exemplified by squamous cell skin cancer. SPCs associated with gallbladder and bile duct cancers suggest predisposition to mutations in the mismatch repair gene MLH1.
000170192 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000170192 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000170192 650_7 $$2Other$$acancer etiology
000170192 650_7 $$2Other$$acancer incidence
000170192 650_7 $$2Other$$ahepatobiliary cancer
000170192 650_7 $$2Other$$arelative risk
000170192 650_7 $$2Other$$asecond primary cancer
000170192 7001_ $$0P:(DE-HGF)0$$aSundquist, Kristina$$b1
000170192 7001_ $$00000-0001-7228-5015$$aSundquist, Jan$$b2
000170192 7001_ $$aChen, Tianhui$$b3
000170192 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b4$$udkfz
000170192 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b5
000170192 7001_ $$aLiska, Vaclav$$b6
000170192 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b7$$udkfz
000170192 773__ $$0PERI:(DE-600)2494772-6$$a10.2147/CLEP.S318737$$gVol. 13, p. 683 - 691$$p683 - 691$$tClinical epidemiology$$v13$$x1179-1349$$y2021
000170192 909CO $$ooai:inrepo02.dkfz.de:170192$$pVDB
000170192 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000170192 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a c020$$b1
000170192 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000170192 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000170192 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000170192 9141_ $$y2021
000170192 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN EPIDEMIOL : 2019$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-01-26
000170192 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-26
000170192 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-26
000170192 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000170192 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000170192 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x2
000170192 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000170192 980__ $$ajournal
000170192 980__ $$aVDB
000170192 980__ $$aI:(DE-He78)C050-20160331
000170192 980__ $$aI:(DE-He78)C020-20160331
000170192 980__ $$aI:(DE-He78)B062-20160331
000170192 980__ $$aI:(DE-He78)HD01-20160331
000170192 980__ $$aUNRESTRICTED